Sars-cov-2
Conditions
Keywords
sars-cov-2
Brief summary
This is an interventional, multi-center, randomized study. Adults with confirmed covid-19 disease not more than 10 days before enrollment date will be recruited (n=1000). Patients in same condition who get treated with standard of care will be randomly assigned to the control group (n=1000), and patients in same condition who get treated with standard of care will be randomly assigned to the placebo group (n=1000). The investigators analyze the effect of Xagrotin, and also investigate impact of different characteristics for instance gender, age, duration of disease, smoking habits and concomitant diseases on the outcome.
Detailed description
An interventional, multi-center, randomized study that will performe in an outpatient setting (n=1000). Adults with confirmed covid-19 disease not more than 10 days before enrollment date will be recruited. Patients in same condition who had treated with standard of care will randomly assign to the control group (n=1000), and patients in same condition who get treated with standard of care will be randomly assigned to the placebo group (n=1000). The investigators analyze the effect of Xagrotin, and also investigate impact of different characteristics for instance gender, age, duration of disease, smoking habits and concomitant diseases on the outcome. Adverse events will be registered.
Interventions
DRUGXagrotin
A herbal compound
DRUGGreen tea
Normal green tea
Sponsors
Biomad AS
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Age 18 or higher * Newly diagnosed (no longer than 10 days) * PCR or clinically confirmed Covid-19
Exclusion criteria
* Coronavirus patients admitted to medical centers for hospitalization and receive medical treatment and necessary care in medical centers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | 30 days | Number of Participants who die by day 30 after the enrollment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Disease From Beginning of Treatment | 30 days | Number of days the patient has experienced the symptoms |
| Hospitalization | 30 days | Number of participants who have been hospitalized for Covid-19 |
| Duration of Hospitalization When Occurred | 30 days | Days the participants were hospitalized |
Countries
Iraq
Contacts
Primary ContactDana Omer, PhD
Outcome results
None listed